ClinicalTrials.gg
WithdrawnNCT05926349ANNEXA-RSUpdated Oct 26, 2024

A Study of Andexanet Alfa in Patients Requiring Urgent Surgery or Procedure

A Phase 3 interventional study of Andexanet alfa and Usual Care in Urgent Surgery, sponsored by AstraZeneca. Withdrawn. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2024-10-26.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Business decision

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Study summary

The study will aim to find out if the drug andexanet alfa is safe and effective in preventing major bleeding during urgent surgery or invasive procedures. The study will compare the use of andexanet alfa to the usual care given at the study center.

Read the detailed description

This study will be an open-label, randomised, controlled, prospective, multicenter study. The study will include patients requiring urgent surgery or procedure that needs to be performed within 15 hours of the last dose of blood-thinning drug (direct oral activated Factor X (FXa) inhibitor).

The study will comprise of the following periods:

  • Screening, followed by surgery or procedure and study intervention.
  • Follow-up period: there will be four follow-up visits over a duration of approximately 30 days.
  • Follow-up visit for patients with positive anti-andexanet alfa antibody test: patients with a positive anti-andexanet alfa antibody response at day 30 will have a follow-up anti-andexanet alfa antibody test approximately 120 days post-surgery or procedure.

Patients will be randomised in the ratio of 1:1 to receive either andexanet alfa or usual care.

02

Conditions studied

  • Urgent Surgery

Keywords

  • Andexanet alfa
  • Blood Thinners
03

In context

Lead sponsor

AstraZeneca is the lead sponsor of 3,503 studies on the registry; 273 are open to participants now.

Of its 369 completed or terminated interventional studies of FDA-regulated products, 178 (48%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patient requires, in the opinion of the Investigator, urgent surgery or procedure and requires reversal of direct oral FXa inhibition.
  • The patient requires urgent surgery or procedure within 12 hours of .
  • The patient requires urgent surgery or procedure that is expected to be associated with a high risk of bleeding or bleeding to occur into a critical organ.
  • The patient has taken an oral FXa inhibitor (such as apixaban, rivaroxaban, or edoxaban) within 15 hours or more, prior to start of surgery or procedure.
  • Female patients of must have a negative pregnancy test at Screening.
  • Willingness to use highly effective methods of (for male and female patients who are fertile).

Exclusion criteria

Exclusion Criteria:

  • The patient requires surgeries or procedures that have a very low chance of causing significant, uncontrollable bleeding, such as small skin procedures, cataract surgery, and minor dental procedures.
  • The patient has acute life-threatening bleeding at the time of Screening.
  • The patient will undergo a surgery or procedure which will require the use of heparin.
  • Patient who is not expected to live for more than three months due to other health problems or has specifically requested not to be resuscitated if their heart stops beating.
  • Prior to screening, the patient had either experienced low count due to heparin use with or without blood clots or had a genetic condition that affects blood clotting.
  • Patient has acute decompensated heart failure, cardiogenic shock, sepsis, or septic shock at the time of Screening.
  • Patient has history of heparin-induced thrombocytopenia (with or without thrombosis) or inherited coagulopathy (eg, anti-thrombin III deficiency, anti-phospholipid antibody syndrome, protein C/S deficiency, Factor V Leiden) at the time of Screening.
  • Previously diagnosed with a bleeding disorder (eg, platelet function disorder, hemophilia, Von Willebrand disease, or coagulation factor deficiency).
  • Prior known to andexanet alfa.
  • Use of andexanet alfa 30 days prior to Screening.
  • Patient diagnosed with dementia.
  • Any prohibited medication as determined in the study.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Andexanet Alfa Group

    Patients will receive andexanet alfa as IV bolus followed by an infusion.

    Drug: Andexanet alfa

  • Active comparator
    Usual Care Group

    Patients will receive treatment based on the Investigator's discretion, according to regional, local/institutional guidelines or practices.

    Drug: Usual Care

Interventions

  • Andexanet is a recombinant version of human FXa

    Also known as: Andexxa®, Ondexxya®

  • DrugUsual Care

    As per the label of the chosen usual care product(s) and/or usual care standards.

06

What researchers measure

Primary outcomes

  1. Number of patients achieving effective intraoperative hemostasis

    Intraoperative hemostasis will be assessed according to the categories as per 4-point hemostasis scale: Excellent - Normal hemostasis, Good - Mildly abnormal hemostasis (eg. slight oozing from surgical wounds), Moderate - Moderate abnormality in intraprocedural hemostasis (eg. controllable bleeding), Poor - Severe hemostatic abnormality (eg. severe refractory hemorrhage). Hemostasis will be considered to be effective if the intraoperative hemostasis category is 'excellent' or 'good', and ineffective if the intraoperative hemostasis category is 'moderate' or 'poor'.

    Time frame: From start to the end of surgery or procedure on Day 0

Secondary outcomes

  1. Change from Baseline in anti-FXa activity measured through blood samples

    The ability of andexanet alfa to rapidly reverse the anticoagulation effect of FXa inhibitors by reduction of anti-FXa activity when compared to usual care.

    Time frame: Baseline to start of surgery or procedure

  2. Change from Baseline in anti-FXa activity measured through blood samples

    The ability of andexanet alfa to sustainably reverse the anticoagulation effect of FXa inhibitors by reduction of anti-FXa activity when compared to usual care at two hours post start of surgery or procedure will be assessed.

    Time frame: Baseline to two hours post start of surgery or procedure

Other outcomes

  1. Number of patients with adverse events

    Safety and tolerability will be evaluated in terms of adverse events and serious adverse events.

    Time frame: Screening (Day -1 to Day 0) until follow-up visit (Day 30 or Day 120)

07

Study locations

No study locations are listed for this record.

08

References and documents

Individual participant data

Plan to share: Yes — Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com /ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.

Supporting information: Study protocol

Time frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles. For details of our timelines, please refer to our disclosure commitment at: https://astrazenecagrouptrials.pharmacm.com /ST/Submission/Disclosure.

Access criteria: When a request has been approved AstraZeneca will provide access to the de-identified individual patientlevel data in an approved sponsored tool. Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information. Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at: https://astrazenecagrouptrials.pharmacm.com /ST/Submission/Disclosure.

Data sharing details ↗ · astrazenecagroup-dt.pharmacm.com

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Aug 2024; primary completion for Jan 2027, 29 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 9, 2023
First posted
Jul 3, 2023
StartEst.
Aug 2, 2024
Primary completionEst.
Jan 5, 2027
CompletionEst.
Sep 7, 2027
Last update
Oct 26, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 26, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05926349
Lead sponsor
AstraZeneca
Responsible party
Sponsor
First posted
Jul 3, 2023
Start date
Aug 2, 2024 (estimated)
Primary completion
Jan 5, 2027 (estimated)
Completion
Sep 7, 2027 (estimated)
Last update
Oct 26, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Oct 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: PRT064445

Start the discussion